Transcatheter edge-to-edge repair (TEER) with MitraClip has demonstrated its benefit compared with complete guideline-directed medical therapy (GDMT), according to the results of the COAPT Study. While cerebrovascular events (CVE), such as stroke or transient ischemic attack (TIA), are rare, they can occur during the procedure (transseptal puncture, device positioning, or device release) or during follow-up...
▶ We keep sharing the experience “MIL Train More MIL – SOLACI”, our program on structural heart disease for Latin American Women Interventionists 🩺 Our scholarship program on structural heart disease continues to thrive in specialized centers in Argentina. 🏥 Today was Favaloro Foundation’s turn. ▶ Here is the complete scientific program of day 4...
In last few years, transcatheter edge-to-edge repair (TEER) with MitraClip has been shown safe and effective, both for primary and secondary mitral valve regurgitation (MR), given the increasing interventionist and echocardiographer experience. However, there is a group of patients that require surgery after failed TEER, either because of bad evolution or because device implantation...
Transcatheter edge-to-edge mitral valve repair with Mitraclip has become a valid strategy to treat mitral valve regurgitation (MR) when surgery is not viable. However, after discharge, residual MR (>moderate) can affect over 10% of patients, because of the use of anesthesia, which alters pre and post procedural measurements. In this context, eco-stress could become a...
Edge-to-edge treatment has proven to be a safe and effective technique in follow-up, decreasing mortality and hospitalizations for heart failure when a good result is achieved. The MitraScore was developed to assess the outcome at the end of the procedure. In that sense, results <3 represent mild mitral regurgitation, which would be related to lower...
Secondary ischemic and non-ischemic mitral valve failure (SMR), produce left ventricle dilation, papillary muscle displacement, and impaired leaflet closure causing regurgitation. This will lead to ventricular function deterioration and bad prognosis. Edge-to-edge mitral valve repair with MitraClip has been shown safe and effective to treat SMR in the short term, but its evolution at 5...
The five year outcomes of the multicenter open label COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) were presented at ACC 2023; it included 614 patients with cardiac failure (CF) and moderate to severe (3+/4+) symptomatic secondary mitral regurgitation, despite medical therapy. Patients were randomized 1:1...
Discover the most read scientific articles on interventional cardiology of 2022 in our website. We Should Treat Significant Stable CAD in Patients Undergoing TAVR Aortic stenosis is associated to significant coronary artery disease (CAD) in nearly 50% of cases. When we decide to treat aortic disease using surgery, it has been established we should also treat...
At present, cardiogenic shock continues to present high mortality despite the new treatments and ventricular assistance devices available in some centers. In this group, the presence of severe mitral regurgitation (MR) is around 5% and, on many occasions, it cannot be treated with surgery because of hemodynamic conditions. Edge-to-edge repair has been looked at by...
There has been an increase in the diagnosis of patients with proven ischemia who did not present obstructive coronary lesions (defined as the absence of stenosis ≥50%), called ischemia with non-obstructive coronary arteries (INOCA). These patients are at a higher risk for major adverse cardiac events (MACE) compared with the rest of the population. The...